Epoprostenol

DB01240ApprovedInvestigationalSmall moleculeProstacycline VasodilatorVasodilating Agents

Epoprostenol is a vasodilator and platelet aggregation inhibitor used for the management of primary pulmonary hypertension and pulmonary hypertension in patients with heart failure. A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation.

Chemical structure of Epoprostenol
Mechanism
Curator reviewed
Primary indication
For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.Curator reviewed · 2 structured indications
Formula / weight
C20H32O5 · 352.4651 g/mol (avg)
First approval
Canada, 2001 · United States, 1995
Also known as
Prostacyclin · Prostaglandin I2 · Prostaglandin X · Vasocyclin
Code names
ACT-385781A · U-53,217
Brand names
  • Flolan
  • Veletri

Resolves to

Structure
InChIKeyKAQKFAOMNZTLHT-OZUDYXHBSA-NSMILES[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,512Drug interactionsStructured to mechanism, not free text
Sign in
37Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
51Marketed productsAcross 7 countries and 19 labellers
Sign in
1ATC codeIncluding every combination product, plus 23 drug categories
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Epoprostenol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account